Carpmaels & Ransford has appointed two life sciences attorneys as partners, effective yesterday, July 1.
The controversial supplementary protection certificate manufacturing waiver has come into force today, July 1.
US drug maker AbbVie has agreed to buy Allergan, the Ireland-headquartered maker of Botox, for $63 billion, in the latest blockbuster deal for the pharmaceutical industry.
Pfizer’s attempt to secure an Arrow declaration in relation to its proposed launch of a cancer drug in Europe was shot down yesterday, June 20, by the English High Court.
British-based pharmaceutical company GSK has entered into a five-year collaboration with the University of California to explore how gene mutations cause disease and accelerate drug discovery.
The EU’s General Court has upheld the European Union Intellectual Property Office’s finding that a trademark for dietary supplements was descriptive of the relevant services to an Italian speaking public.
Biopharmaceutical company Sensorion has entered into a research collaboration with French research body Institut Pasteur.
Four pharmaceutical companies allegedly agreed not to compete for the supply of an anti-nausea tablet to the National Health Service, according to objections filed by the UK Competition and Markets Authority.
Elkington + Fife has unveiled Mark Scott as a new partner in the UK firm’s patent practice.
Novartis is set to acquire assets associated with Xiidra ((lifitegrast ophthalmic solution), a dry eye treatment, from Takeda.